GMMMG logo

NHS photos

NHS logo

GMMMG Consultations

 

On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below.

Title

Information

Feedback

End date

06

Biologics Pathways for Inflammatory Bowel Disease in Adults

The Greater Manchester biologics pathway for inflammatory bowel disease has been updated with input from clinical specialists and with the support of Greater Manchester Shared Service. This version has been updated to incorporate NICE TA456: Ustekinumab to treat moderately to severe Crohn’s disease.

This pathway is intended for use in patients with severe Crohn’s disease and moderately to severely active ulcerative colitis, within the Greater Manchester health economy.

We seek the comments of all GM NHS healthcare professionals.

This consultation period is open until 5pm Friday October 27th 2017, comments should be submitted via the Feedback Form

Representatives of the pharmaceutical industry are invited to comment on factual inaccuracies only.

Feedback Form

5pm Friday
27th Oct 2017

05

Botulinum toxin commissioning policy - DRAFT 0.6

Supporting information to compliment the draft Greater Manchester botulinum toxin policy draft

A draft copy of the Greater Manchester botulinum toxin commissioning policy is currently open for GM wide consultation. Comments from GM NHS healthcare professionals are invited.

A supporting information document to compliment the draft Botulinum toxin commissioning policy is also available

Industry may comment on factual inaccuracy of this content only.

This consultation period is open until 5pm on 6th November 2017, comments should be submitted via the Feedback Form.

Feedback Form

5pm Monday
6th Nov 2017

04

Draft copy of the updated GMMMG formulary
chapter 13 Skin

A draft copy of the updated GMMMG formulary chapter 13 Skin is currently open for GM wide consultation. Comments from GM NHS healthcare professionals are invited.

Industry may comment on factual inaccuracy of this content only.

This consultation period is open until 5pm on 27th October 2017, comments should be submitted via the Feedback Form

Feedback Form

5pm Friday
27th Oct 2017

03

Proposed changes to the GMMMG  RAG and DNP classifications

The Formulary and Managed Entry Subgroup have proposed the following RAG and DNP classifications, and now invite comments on these proposals from GM stakeholders.

Industry are invited to comment on factual inaccuracy only.

Please submit any comments here by 5pm on 10th November 2017.

Feedback Form

5pm Friday
10th Nov 2017

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer